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Type 1 diabetes (T1D) is a chronic immune-mediated disease in
which the insulin-producing beta cells of the pancreatic islets are
destroyed. The disease process starts often at a young age, during the
ﬁrst years of life. In T1D-affected patients, the lack of endogenous insu-
lin causes a life-long need of exogenous insulin therapy [1,2]. The rate of
T1D has increased conspicuously after World War II in most developed
countries. For example, in Finland the incidence among children under
the age of 15 years has increased from 12 to 65 new cases/100,000/
year in ﬁve decades [3]. The increasing disease rate cannot be explained
by genetic factors but implies that these changes are an outcome of in-
teractions between the modern westernized environment and predis-
posing genes.
The human intestinalmicrobiomematurates during theﬁrst years of
life, after which its composition resembles the composition observed in
adults [4,5]. The maturation of the gut microbiome is closely linked to
the development of the immune system [6]. Three contemporary phe-
nomena occurring in early childhood – the dynamic development of
the immune system, th the maturation of the gut microbiome, and the
appearance of the ﬁrst T1D-associated autoantibodies – raise the ques-
tion whether these phenomena are only temporarily associated, or do
they reﬂect causative relationships. Even if theﬁeld ofmicrobiome stud-
ies has expanded remarkably during recent years, causal relationships
have not been established. Since our last review in which we explored
the potential role of the gut microbiota in the development of T1D [7],
ample new data has been generated. In this review, we set out to sum-
marize recent ﬁndings from the microbiome studies.
2. Intestinal bacterial microbiota
2.1. Lessons learned from experimental studies
The idea that intestinal microbiota might play an important role in
the development of immune-mediated diseases, such as T1D, was pre-
sented already in the 1980's [8]. To test this hypothesis, genetically
modiﬁed rodents have been raised in germ-free conditions; colonized
with variousmicrobial communities; treatedwith probiotics, prebiotics,
and antibiotics; fed with distinct diets, and given intestinal microbiota
from other animals (Supplementary Table 1). Considering the interplay
between the ntestinal microbiota and the developing immunity, several
key ﬁndings have been observed (Table 1). Comparisons between these
ﬁndings and those observed in man (Table 2) will be discussed in the
next paragraphs [9–31]. While interpreting the results, one should
bear in mind that autoimmune diabetes observed in NOD mice is not
identical with T1D in humans [32]. Considering these two species, twoTable 1
Summary on ﬁndings from experimental studies on the interplay between the intestinal
microbiota and exogenous and host-related factors.
• Genetic setup of the host is associated with a tendency towards a speciﬁc
microbial composition
• Microbial communities mature early in life
• Intestinal microbiota affects the incidence of immune-mediated diseases
• Prolonged or repetitive deviation from the optimal microbial homeostasis
(dysbiosis) may lead to loss of self-tolerance and spreading of proinﬂammatory
signals and effector cells
• In spite of a plethora of microbes, the functional net effects of the co-occurring
microbial colonies resemble each other
• Considering the whole superorganism (host with its microbiota), crosstalk net-
works are extensive, ranging from molecular interactions to communication
between microbiota and various organs of the host
• Sum vectors of these crosstalk networks may point towards proinﬂammatory or
anti-inﬂammatory reactivity
• Modulation of the intestinal microbiota may lead to prevention or enhancement
of the immune-mediated disease process, depending on the resulting composi-
tional and functional changes
• Nutritional factors drive rodents towards tolerance or diseasemajor differences associatewith the timing of the disease development:
(i) in man, seroconversions peak during the ﬁrst three years of life,
while NOD mice typically seroconvert close to their sexual maturity,
and (ii) approximately half of the cases appear before adulthood in
humans, whereas in NOD mice, nearly all cases occur in adult animals,
the typical age of onset being 12–30 weeks. Importantly, by 30 weeks
of age, N80% of the NOD females and N50 of the NODmales are typically
overtly diabetic, while in human populations the prevalence of T1D is
under 1% [33].
2.2. The interactions between the genetic setup, nutrition, microbial compo-
sition, and susceptibility to islet autoimmunity
The genetic setup of the hostmay affect the host's microbial compo-
sition and function, the activation of innate and adaptive immunity and
susceptibility to various diseases; both in animal models and in man
[34–36]. In mice, the host's inherited disease susceptibility can be mod-
iﬁed by colonizing with selectedmicrobes, providingmice with speciﬁc
diets, or treating themwith antibiotics. Results from these interventions
range from accelerated autoimmunity to total prevention of the disease
(Supplementary Table 1). In humans, dietary modiﬁcations, such as
weaning infants to highly hydrolysed formula after exclusive breast-
feeding [37] or delaying the introduction of gluten-containing foods in
infancy [38], have not provided any disease protection. The same
holds true with oral antigens [39] and nicotinamide, a form of vitamin
B3 suggested to protect beta-cells from destruction [40]. However, one
observation from children with HLA-conferred disease susceptibility
implies that early oral exposure to probiotics may decrease the risk of
islet autoimmunity [41]. The protective effect was restricted to children
carrying the high-risk HLA DR3/4 genotype. Recently, two intervention
studies aimed at preservation of endogenous insulin secretion have
been launched: one with L. rhamnosus GG and B. lactis Bb12 in children
with newly diagnosed T1D, and one pilot study with prebiotic
oligofructose-enriched inulin in children with a T1D duration of at
least one year [42,43].
2.3. Intestinal microbiota matures early in life and affects the incidence of
immune-mediated diseases
The humanmicrobiota maturates early in life. After being born from
nearly sterile conditions, children encounter a lot of microbes and envi-
ronmental antigens before reaching their third year of life, by which the
intestinal microbiota has reached its adult-like composition and relative
stability. Fromearly on, themainmodiﬁers of themicrobial composition
are the route of delivery, early nutrition (especially breast-feeding and
introduction of supplementary feeding), use of antibiotics, and the mi-
crobial exposure and the hygiene level of the immediate environment
[44,45]. Considering T1D, signiﬁcant changes occur in the gut microbi-
ota before any systemic signs of islet autoimmunity. These changes
occur early in life and have a far-reaching effect on the development
of the immune system [12,30,46,47]. In rodents, progression to autoim-
mune diabetes associates with altered composition and diversity of the
intestinal microbial colonies, reduced abundance of Firmicutes in rela-
tion to Bacteroidetes, and decrease in butyrate-producing bacteria sub-
groups. This dysbiosis coincide with increased intestinal permeability,
translocation of microbial materials through the epithelium, and in-
creased and aberrant presentation of foreign and self-antigens. These al-
terations activate proinﬂammatory pathways in the gut, in the regional
lymph nodes, and in the pancreas (Supplementary Table 1). In humans
developing T1D, two comparable ﬁndings have been reported regard-
less of geographical location: the proinﬂammatory environment in the
gut and the combination of an increased relative abundance of
Bacteroidetes together with decreased levels of Firmicutes (Table 2).
More speciﬁcally, in a recent study where young children with HLA-
conferred disease susceptibility and signs of islet autoimmunity were
compared to matched controls, the controls had higher levels of
Table 2
Recent studies investigating the associations between gastrointestinal microbiota and islet autoimmunity leading to type 1 diabetes (T1D) in humans.
Ref.
#
Author Age
(years)
Study groups; Geographical locations Findings related to T1D and/or islet autoimmunity
[9] Mejía-León ME
et al. 2014
7–18 Children with T1D at diagnosis (n= 8) and after 2 years of insulin
treatment (n = 13) vs. healthy controls (n = 8); Mexico
At diagnosis, T1D patients had high levels of Bacteroides, whereas
controls had Prevotella dominance. After 2 years of insulin treatment,
cases resembled the controls.
[10] Kemppainen KM
et al. 2015
0–2 Seronegative young children with high risk HLA genotype
(n= 15 from each site); Finland, Sweden, Germany, and USA
Bacterial diversity differed by geographical location. Children from
Finland and Colorado had lower bacterial diversity, and children from
Sweden and Washington state had Biﬁdobacterium dominance.
[11] Soyucen E et al.
2014
6–15 Children with newly diagnosed T1D (n = 35) and healthy controls
(n= 35); Turkey
Compared to controls, Biﬁdobacterium colonization was lower in
patients with T1D. Candida albicans and Enterobacteriaceae (other than
Echerichia coli) were increased in controls.
[12] Kostic AD et al.
2015
0–3 Young children with islet autoimmunity (n = 11) and healthy
controls (n = 22). All have HLA-conferred risk for T1D; Finland and
Estonia
Drop in alpha-diversity between seroconversion and T1D diagnosis,
accompanied with an increase in proinﬂammatory organisms, changes
in gene functions, and serum and stool metabolites. Microbial
relationships were shared across most subjects. Strain compositions
were highly variable between individuals, but stable within
individuals throughout infancy. Metabolic composition and metabolic
pathway abundances were constant across time.
[13] Endesfelder D
et al. 2016
0–3 Young children with persistent islet autoimmunity (n = 22) and
healthy controls (n = 22); Germany
Bacteroides-dominated subgroup associated with early introduction of
non-milk diet, increased risk for early autoantibody development, and
lower abundances of genes for butyrate production. Alterations in the
composition of mucin-degrading bacteria associated with early
development of islet autoimmunity. Functional associations between
diet, gut microbiome and islet autoimmunity existed in microbial
co-occurrence networks.
[14] Heintz-Buschart
A et al. 2016
5–62 Four families with ≥2 generations of ≥2 cases of T1D per family
(n = 20); Netherlands
Family membership has a pronounced effect on the structural and
functional composition of the gastrointestinal microbiome. No
differences in taxonomic or functional diversity and richness between
T1D cases and their family members. Protein expression ﬁndings
implicated that T1D cases may have slightly dysfunctional exocrine
pancreas.
[15] Maffeis C et al.
2016
6–16 Children with islet autoimmunity (10) and healthy controls
(n= 10); Italy
Group-speciﬁc differentiation between cases and controls was
challenging. Intestinal permeability was higher in children with islet
autoimmunity. Dialister invisus, Gemella sanguinis and Biﬁdobacterium
longum were associated with prediabetes.
[16] Qi CJ et al. 2016 10–15 Children with T1D (n = 15) and healthy controls (n = 15); China T1D cases had decreased bacterial richness, decreased Haemophilus,
Lachnospira, Dialister, and Acidaminococcus, and increased Blautia
levels. Percentage of Blautia correlated with HbA1c, number of
T1D-associated autoantibodies, and IA-2A levels.
[17] Vatanen T et al.
2016
0–3 Young children with HLA-associated risk for T1D (n= 74 from each
country); Finland, Estonia, and Russia
Bacteroides strains were more abundant in Finnish infants compared to
Russian Karelian infants, while E. coli was more frequent on Finnish
infants Bacteroides LPS had immunoinhibitory properties that may
preclude early immune education and contribute to development of
T1D, while E. coli derived LPS was strongly immunostimulatory.
Metabolism of human milk oligosaccharides (HMOs) maintained
Biﬁdobacterium-dominant versus Bacteroides-dominant gut microbiota
in the ﬁrst year of life.
[18] Cinek O et al.
2017
0–3 Young children with islet autoimmunity progressing to T1D
(n= 18) and healthy controls (18); Finland
Four operational taxonomic units were less abundant in children
developing islet autoimmunity, most markedly Bacteroides vulgatus
and Biﬁdobacterium biﬁdum. Potential relation existed between
CrAssphage and Bacteroides dorei. No differences were observed
between cases and controls in alpha or beta diversity, or the taxonomic
levels of bacterial phyla, classes or genera.
[19] de Groot PF
et al. 2017
25–45 Adults with T1D (n = 53) and healthy controls (n = 50);
Netherlands
Both oral and gut microbiota differed between cases and controls. Oral
microbiota had higher abundance of streptococci in cases, while gut
microbiota showed decreased butyrate-producing species and less
butyryl-CoA transferase genes. Plasma levels of acetate and propionate
were lower in T1D. Christensenella and Subdoligranulum strains
correlated with glycaemic control, inﬂammatory parameters, and level
of short-chain fatty acids (SCFAs).
[20] Pellegrini S et al.
2017
1–65 Children and adults with T1D (n = 19) or celiac disease
(CD, n = 19) vs. controls (n = 16); Italy
T1D-speciﬁc increase in monocyte/macrophage inﬁltration in the
intestinal biopsies. Cases had increase in Firmicutes and
Firmicutes/Bacteroidetes ratio, and a reduction in Proteobacteria and
Bacteroidetes in the duodenal mucosa. The expression levels of genes
speciﬁc for T1D inﬂammation were associated with the abundance of
speciﬁc bacteria in the duodenum.
[21] Pinto E et al.
2017
8–11 Children with T1D (n = 3) and healthy controls (n = 3);
Portugal
T1D cases had a microbial intestinal proteome enriched with proteins
of clostridial cluster XVa and cluster IV and Bacteroides, while controls
had more often biﬁdobacterial proteins. T1D children had lower levels
of exocrine pancreatic enzymes.
[22] Stewart CJ et al.
2017
25–30 Young adults with T1D (n= 10) and healthy controls (n = 10); UK Faecalibacterium sp., Roseburia sp. and Bacteroides sp. were the most
abundant microbes in both groups. Each bacterial proﬁle was
individual and no signiﬁcant differences in the proﬁles or in the
diversity indices were observed between the groups.
[23] Cinek O et al.
2018
7–15 Children at T1D onset (n = 73; 14–20 per country) and healthy
controls (n = 104); Azerbaijan, Jordan, Nigeria, and Sudan
Genus Escherichia spp. correlated with T1D. T1D cases showed an
inverse association with Eubacterium and Roseburia (Firmicutes), and
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Table 2 (continued)
Ref.
#
Author Age
(years)
Study groups; Geographical locations Findings related to T1D and/or islet autoimmunity
clostridial clusters IV and XIVa. No T1D-associations for microbial
richness or enterotypes were observed.
[24] Gao X et al.
2018
0–3 Young children with islet autoimmunity (n = 11) and healthy
controls (n = 22). All have HLA-conferred risk for T1D; Finland and
Estonia
More microbial interactions and the inhibition of Clostridia by
Gammaproteobacteria were maintained throughout the ﬁrst 3 years of
life in healthy children. Gammaproteobacteria inhibited Bacteroidia in
the cases, but not in controls. The inhibitory effects from Actinobacteria
and Bacilli on Bacteroidia, from Bacteroidia on Clostridia, and the
beneﬁcial effect from Clostridiao on Bacteroidia were shared between
cases and controls.
[25] Gavin PG et al.
2018
2–45 Children and adults with recent-onset T1D (33) or islet
autoimmunity (n = 17), and low-risk autoantibody-negative
subjects (n = 29) and healthy controls (n = 22); USA
T1D patients had increased intestinal inﬂammation and decreased
barrier function. Microbial taxa capable of promoting the host's
mucous barrier, microvilli adhesion, and functions of the exocrine
pancreas were depleted in T1D. Pancreatic exocrine dysfunction
appeared in high-risk individuals before the disease onset. Both
host-derived and microbial-derived proteins were able to differentiate
the new-onset and the islet autoantibody-positive subjects from the
low-risk subjects.
[26] Higuchi BS et al.
2018
15–35 Teenagers and young adults with T1D (n = 20) and healthy
controls (n = 28); Brazil
T1D patients had intestinal dysbiosis with prevalent Gram-negative
bacteria like Bacteroides vulgatus, Bacteroides rodentium, Prevotella
copri, and Bacteroides xylanisolvens. Cases had increased plasma levels
of the proinﬂammatory interleukin-6. Poor glycaemic control
associated with the relative abundance of Bacteroidetes,
Lactobacillales, and Bacteroides dorei.
[27] Huang Y et al.
2018
18–25 Young adults with T1D (n = 12) and healthy controls (n = 10);
China
Various bacterial taxonomic clades differed between cases and
controls. Bacteroidetes and Firmicutes were the dominant phyla in
cases and controls, respectively. Abundance of Faecalibacterium
correlated inveresly with HbA1c levels. Numbers of islet
autoantibodies correlated positively with Bacteriodes and Bilophila
abundances and inversely with Streptococcus and Ruminococcaceae
abundances.
[28] Leiva-Gea I et al.
2018
9–16 Children with T1D (n = 15) or MODY2 (n = 15), and healthy
controls (n = 13); Spain
T1D associated with (i) lower microbial diversity, (II) higher relative
abundance of Bacteroides, Ruminococcus, Veillonella, Blautia, and
Streptococcus genera, and (III) lower relative abundance of
Biﬁdobacterium, Roseburia, Faecalibacterium, and Lachnospira.
Proinﬂammatory cytokines and lipopolysaccharides were increased in
T1D cases, as were the expression of genes related to lipid and amino
acid metabolism, ATP-binding cassette transport, lipopolysaccharide
biosynthesis, arachidonic acid metabolism, antigen processing and
presentation, and chemokine signalling pathways. MODY2 associated
with higher Prevotella abundance and a lower Ruminococcus and
Bacteroides abundance. Intestinal permeability was increased both in
T1D and in MODY2 cases.
[29] Mejía-León ME
et al. 2018
9–14 Children with newly diagnosed T1D (n = 10) The increasing Bacteroides proportion (during the ﬁrst months after
diagnosis) correlated with the consumption of saturated fat and
carbohydrates at 3 months. After adjusting for HbA1C, consumption of
carbohydrates associated with decreased Bacteroides abundance over
time.
[30] Stewart CJ et al.
2018
0–4 Young children (n= 903) with high risk HLA genotype; Finland,
Sweden, Germany, and USA
Feeding with breast milk was the most signiﬁcant factor associated
with the microbiome structure. It associated with higher levels of
Biﬁdobacterium sp. (B. breve and B. biﬁdum). Bacteroides associated
with increased microbial diversity and faster maturation of the gut.
Only subtle associations were observed between microbial taxonomy
and islet autoimmunity: i) higher relative abundance of an
unclassiﬁed Erysipelotrichaceae in children with autoimmunity; ii)
ﬁve bacterial genera associated with T1D onset (Parabacteroides the
most signiﬁcant); iii) eleven bacterial genera were lower in T1D cases,
including four unclassiﬁed Ruminococcaceae, Lactococcus,
Streptococcus, and Akkermansia.
[31] Vatanen T et al.
2018
0–4 Young children (n= 783) with high risk HLA genotype developing
persistent islet autoimmunity or T1D vs. controls; Finland, Sweden,
Germany, and USA
Control children had more genes associated with fermentation and
biosynthesis of SCFAs. T1D-associated microbial compositions were
taxonomically diffuse but functionally more coherent. Compared to
children with autoimmunity, controls had higher levels of Lactobacillus
rhamnosus and Biﬁdobacterium dentium, while children with
autoimmunity had higher abundance of Streptococcus group
mitis/oralis/pneumoniae species. Compared to children developing T1D,
controls had higher levels of Streptococcus thermophiles and
Lactococcus lactis species. T1D cases had higher levels of
Biﬁdobacterium pseudocatenulatum, Roseburia hominis, and Alistipes
shahii.
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516 H. Siljander et al. / EBioMedicine 46 (2019) 512–521Lactobacillus rhamnosus and Biﬁdobacterium dentium, while children
with autoimmunity had higher abundance of the Streptococcus group
mitis/oralis/pneumoniae species. When children progressing to T1D
were compared to non-progressors, the latter had higher levels of Strep-
tococcus thermophilus and Lactococcus lactis, whereas the progressors
had increased levels of Biﬁdobacterium pseudocatenulatum, Roseburia
hominis, and Alistipes shahii species. The intestinal microbiomes of the
control children had alsomore genes related to fermentation and to bio-
synthesis of short-chain fatty acids [31]. Other recent analyses on the
host-microbiome interactions have also revealed that factors promoting
the host'smucosal barrier, adhesion of themicrovilli, and exocrine func-
tion of the pancreas are depleted in T1D patients [21,25]. Some seem-
ingly contradictory ﬁndings observed in man (Table 2), may be at
least partly explained by non-optimal selection of controls, or by the dif-
ferences in sample collection and handling as well as in sequencing
methods.A) HEALTHY INTESTINAL ENVIRONMENT
MI
CR
OB
IO
TA
• Stabile and resilient microbial colonization maintaining symbiosis and homeostasis
• Firmicutes >> Bacteroides
• Beneficial synergistic relations between fungi, bacteria, and bacteriophages
• Constrained niches for pathobionts (compete for nutrients and space)
• Producers of SCFAs and mucin metabolites promote intestinal integrity and well-being
•
•
•
•
•
•
HO
ST
• Intact epithelium and firm tight junctions
• Appropriate regeneration in the intestinal epithelium
• Controlled and restricted transportation of foreign antigens and other molecules
• Regulation of the inflammatory stimuli
• Normal presentation of foreign antigens
• Maintenance of self-tolerance and optimal development of the immunity
•
•
•
•
•
•
Fig. 1. Healthy intestinal environment (A) compared to dysbiosis (B) that leads to intestinal in
TGF-β, transforming growth factor beta; IL, interleukin; LL-37,cathelicidin-related antimicr
defensin-2 (HβD2); TNFα , tumor necrosis factor alfa; IFNγ, interferon gamma. Symbols:
cell; Firmicutes; Bacteroides; opportunistic pathobionts;
Bacteriophage; foreign antigens; self antigens.It appears that in man, a prolonged or repetitive deviation from the
optimal microbial homeostasis (dysbiosis) may lead to loss of self-
tolerance and systemic spreading of the proinﬂammatory signals and
effector cells. Thus far it has been suggested that a health-promoting in-
testinal microbiota (i) has a certain level of microbial abundance, the
optimal quantity of which depends on the functional net effects of the
co-occurring microbial networks, (ii) has a composition that is resilient
to transient perturbations, such as antibiotic treatment or gastrointesti-
nal infections, (iii) provides the host with protection against pathogen
invasions, and (iv) provides the host and the co-occurring commensal
microbes with nutritional metabolites they are otherwise unable to ob-
tain, e.g. certain vitamins, degraded complex polysaccharides, butyrate,
and mucin metabolites (Fig. 1) [13,48].B) DYSBIOSIS LEADING TO INTESTINAL INFLAMMATION AND AUTOIMMUNITY
Microbial colonization unstable and susceptible to disturbances
Bacteroides >> Firmicutes
Reduced microbial diversity and/or aberrant microbial composition
Decreased richness and beta diversity of the intestinal virome
Overgrowth of opportunistic pathobionts
Mucin-degraders disappear and number of butyrate-producers decreases
Integrity of the intestinal barrier disturbed and permeability increased
Calprotectin and human beta defensin 2 into the intestinal lumen
Translocation of microbial material to lamina propria and adjacent organs
Pro-inflammatory environment both in the intestinal lumen and in the mucosa
Maturation of the immunity disturbed
Presentation of self-antigens, loss of tolerance and development of immune-mediated diseases
ﬂammation and emerging of autoimmunity. Abbreviations: SCFA, short-chain fatty acids;
obial peptide 37; Ref3b, regenerating islet-derived protein 3-beta; HβD2, human beta
dendritic cell; T cell; B cell; plasma
mucin metabolisers like Akkermansia muciniphila; fungi like Candida albicans;
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3.1. Virus and T1D: From infections to virome
Viral infectionshave been associatedwith diabetes since 1864,when
mumps was for the ﬁrst time implicated as a cause of diabetes [49]. In
the 1920's, the observed seasonal variation in the acute diabetes onset
created the hypothesis that diabetes might have an infectious origin
[50,51]. The technical developments in the next three decades rendered
further ﬁndings possible: (i) viral infections can induce diabetes inmice
[52–54], (ii) some patients with newly-diagnosed insulin-dependent
diabetes have neutralizing Coxsackievirus B4 antibodies [55], and (iii)
Coxsackievirus B4 isolated from a patients who died at the diagnosis
of diabetes caused pancreatic islet inﬂammation and beta cell death
when inoculated into mice [56].
Thereafter, the pathomechanisms behind the virus-induced insulitis
and beta-cell autoimmunity leading to T1D have been intensively stud-
ied and discussed [e.g. 57,58]. In addition to Coxsackie B4, other entero-
viruses and related viruses have been shown to induce diabetes in
animals. In humans, enterovirus PCR-positivity has been correlated
with subsequent development of T1D-associated autioantibodies in
at-risk individuals, and post-mortem examinations have shown that
unlike controls, patients with newly diagnosed T1D have beta-cell
tropic destructive Coxsackie viruses in their pancreas [59–62]. The latest
advancement in the ﬁeld is the endeavour to develop a vaccine for pre-
vention of T1D by inducing Coxsackievirus B immunity [63].
Studies on associations between viral infections and T1D have
underlined the highly variable nature of the viruses, e.g. in some mice
models inoculationwith assumedly diabetogenic variants of encephalo-
myocarditis virus or Coxsackie B caused paradoxical protection against
insulitis and diabetes [64,65]. Subsequently, it has been suggested that
certain latent infections might bring immune beneﬁts for the host and
thus represent a part of the host's beneﬁcial virome [66,67].
3.2. Early life dynamics of the intestinal virome in man
Lim et al. have described the dynamics of the early human intestinal
virome in eight twins followed frombirth until the age of two years [68].
For all virus groups, interpersonal variations were signiﬁcantly lower
within the twin pairs than between different pairs of twins. The main
ﬁndings were that in man, populations of eukaryotic viruses have
their nadir at the birth of the child, after which the abundance and the
diversity of both RNA and DNA viruses increase by age. Entero-,
parecho-, tombamo- and sapoviruses were the most common eukary-
otic RNA viruses, while anelloviruses were the most common eukary-
otic DNA viruses. Dynamics of the anelloviruses seemed to reﬂect the
host's immunocompetence: they were rarely seen in breastfed infants
before the age of 3 months but peaked at the age of 6–12 months,
when the immune protection provided by the mother faded, and the
infant's own immunity gradually prevailed.
Bacteriophages, viruses that infect bacteria, were observed in all
samples from these twins and comprised the dominant viral component
of the normal intestinal virome. Contrary to eukaryotic RNA andDNA vi-
ruses, richness and diversity of the bacteriophages peaked at birth and
decreased therafter. Among the bacteriophages, Caudovirales
(Siphoviridae, Inoviridae, Myoviridae and Podoviridae families) and
Microviridae families were the most abundant ones. The abundance of
the two groups of bacteriophages showed an inverse correlation, and
the balance of the bacteriophage populations shifted towards
Microviridae dominance by the age of 2 years. The otherwise commonly
observed human intestinal bacteriophage, CrAssphage, appeared only
in one sample taken at the age of 2 years, indicating that these bacterio-
phages peak at a later age. Predator-prey relationships between bacte-
riophages and their targets showed clear age-dependent trajectories:
after high abundance of bacteriophages and low number of intestinal
bacteria at birth, a decrease in Caudovirales and a shift towardsMicroviridae dominance allowed a physiological increase in the abun-
dance and diversity of the intestinal bacterial colonies by the age of
2 years [68].
3.3. Human intestinal virome and islet autoimmunity
Thus far, there are few clinical studies exploring the role of the intes-
tinal virome in the development of T1D in man [69–71]. In the ﬁrst re-
port, stool samples from 19 case children with early advanced islet
autoimmunity and subsequent progression to clinical T1D, and their
tightlymatched controls, were analysedwith next-generation sequenc-
ing. The detected human viruses were veriﬁed by using real-time PCR
[69]. Samples in focus were gathered 3, 6, and 9 months before the
ﬁrst signs of islet autoimmunity. No dramatic changes in the intestinal
virome preceded the appearance of the T1D-associated autoantibodies
and no associations between islet autoimmunity and any of the de-
tected human viruses were observed. In the second report from the
same DIPP Study cohort, associations between islet autoimmunity and
the intestinal bacteriome (16S rDNA proﬁles) and virome (both DNA
and RNA viruses) were assessed [70]. Compared to controls, four bacte-
rial operational taxonomic units were less abundant in children who
progressed to islet autoimmunity. The concurrent quantitative relation
between bacteriophage CrAssphage and prevalent species of the
Bacteroides genus suggested that CrAssphage might possibly modify
the intestinal bacteriome towards dysbiosis characteristic of islet auto-
immunity [70].
In another small longitudinal study on young Finns and Estonians,
comprising 11 childrenwith T1D-associated autoantibodies and 22 con-
trols, intestinal viromes of the controls had higher diversity and higher
frequency of Circoviridae-related sequences, when compared to cases
[71]. Human enterovirus, kobuvirus, parechovirus, parvovirus, and rota-
virus sequences were frequently detected in the samples, but were not
associated with islet autoimmunity. After adjusting for age, speciﬁc
T1D-associated viral bacteriophage contigs could be identiﬁed. T1D-
associated contigs were statistically linked to speciﬁc components of
the bacterial microbiome, thus indicating an interplay between the
two kingdoms. Results from this study conﬁrmed that certain viral sig-
natures, remarkably consistent across individuals, reﬂect normal intes-
tinal development, and that the observed age-discriminative contigs
are predictive of the developmental changes occurring in the gut
microbiome [71]. The partly contradictory ﬁndings in these three early
studies may, again, be explained by differences in sampling and han-
dling methods, sequencing techniques, or in the identiﬁcation of the
viral sequences. Future larger studies on the role of the intestinal virome
in the development of islet autoimmunity will show whether T1D-
associated alterations in the intestinal bacterial microbiome are inde-
pendent phenomena, or a result from earlier changes in the intestinal
virome. As bacteriophages can modulate bacterial abundance and colo-
nization, changes in their abundance and diversity might well be able to
disturb the intestinal homeostasis and lead to bacterial dysbiosis. On the
other hand, there are already indications that certain eukaryotic viruses
modify mucosal immunity similarly to commensal bacteria, thus
supporting the intestinal homeostasis [72].
4. Intestinal fungal community (mycobiota)
4.1. Mycobiota is an elementary part of the human microbiota
Recent studies of the intestinal microbiome in relation to T1D have
largely focused on the role of alterations in the bacterial community.
The human intestine, however, harbours a diverse range of bacteria,
fungi, viruses, and protista [73,74]. Mycobiota is an important part of
the human microbiota, but its role in various diseases is scarcely
known. As all human barrier surfaces, including mucosa, are colonized
with fungi, alterations in fungal communitiesmay have profound effects
on human health. The intestinal mycobiome may modulate the
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interacting with microbial organisms or indirectly by modulating the
immune system of the host [75]. The development of culture-
independent methods for the identiﬁcation of the fungi has increased
the knowledge of fungal colonization in humans and revealed associa-
tions between organ-speciﬁc diseases and themycobiome. Themodern
methods for identifying fungal communities is based on sequencing the
18 s and 28 s sub-units of ribosomal DNA or so called internal tran-
scribed spacer regions (ITS) [76].
4.2. Intestinal mycobiota in healthy humans
Several fungal species have been identiﬁed in the gastrointestinal
tract of healthy humans, representing approximately 0.1% of the intesti-
nalmicrobiota [77,78]. Stability of the intestinal mycobiota appears lim-
ited, as few fungal species have constantly been observed across
different studies. Within the 36 studies analysed for a recent review,
only 15 of the identiﬁed 267 fungal species were detected in more
than ﬁve studies [77]. Fungal species most commonly detected
belonged to the following genera: Candida, Saccharomyces, Penicillium,
Aspergillus, Cryptococcus, Malassezia, Cladosporium, Galactomyces,
Debaryomyces, and Trichosporon. Themajority (~75%) of the fungal spe-
cies were detected only in one study [77].
4.3. Disease associations of intestinal fungi
Even though it seems plausible thatmycobiota plays an active role in
the maintenance of the intestinal integrity, data on associations be-
tween mycobiota and human diseases is scarce. The main ﬁndings
thus far relate to Saccharomyces cerevisiae and Candida species. Over-
growth of Candida spp. has been observed in humans with T1D or in-
ﬂammatory bowel diseases. Poor glycaemic control may promote
fungal overgrowth, and patientswith established diabetes aremore sus-
ceptible to have frequent and prolonged fungal infections [79]. The
same holds true for immune compromised individuals [80,81]. In
Crohn's disease, increased colonization with Candida species, elevated
levels of antifungal-antibodies against Saccharomyces cerevisiae (ASCA
Ig), and decreased abundance of Saccharomyces cerevisiae in the intesti-
nal mycobiome have been observed [82]. Increased Candida coloniza-
tion in patients with inﬂammatory bowel disease (IBD) may arise
from alterations in the patients' immune system and from the frequent
use of anti-inﬂammatorymedications and antibiotics [83]. In addition to
patients with IBD or autism spectrum disorders, overgrowth of Candida
spp., especially that of C. albicans, has been observed in children with
clinical T1D [11,83–85]. The idea that intestinal mycobiota has a modi-
fying effect on extra-intestinal immunity has been supported by ﬁnd-
ings from a mouse model of allergy in which antibiotic-induced
intestinal overgrowth of Candida promoted airway inﬂammation
[86,87]. Mycobiota may also play its own important role in promoting
the well-being of the mucosal barrier, especially when the bacterial
microbiome is disturbed [88,89].
4.4. Mycobiome-bacteriome interactions
Inter-kingdom crosstalk between bacteria and fungi has been ob-
served in patients with Crohn's disease, among whom fungal genera
correlated with several bacterial taxa [90,91]. The potency of the
mycobiota to regulate the bacterial microbiota is emphasised by ﬁnd-
ings showing that after antibiotic treatment, the restoration of the bac-
terial compartment is considerably inﬂuenced by colonization with
C. albicans [91]. Animals treated with cefoperazone and subsequently
fed with C. albicans had increased level of yeasts accompanied with
other alterations in their intestinal bacterial microbiota [92]. In a
mouse model of liver injury, administration of Saccharomyces cerevisiae
var. boulardii changed the composition of the intestinal bacterial com-
partment by increasing the relative abundance of Bacteroidetes anddecreasing the Firmicutes [93]. The observation that fungal and bacterial
communities interact with each other has been established, but the de-
tailed crosstalk networks and their relevance regarding the health of the
human host are yet to be more thoroughly characterized.
5. Microbiota in other sites
In addition to the gut, microbes colonize a series of other mucosal
and epithelial barriers, such as the oral cavity, airways, skin, and genita-
lia. Data on the immunomodulatory role of the microbiota residing in
other compartments than the intestine is limited. Hu et al. reported
that in the NOD mice, speciﬁc islet autoimmunity related changes in
the intestinal microbiota were predictive for future diabetes, and that
changes in the microbiota were more obvious in the intestine than
other sites [27]. A Dutch study compared the oral and the intestinal mi-
crobiota between adult patients with established T1D and healthy con-
trols [94]. Marked differences were observed in the oral microbiota
between patients and control subjects. In the oral microbiota, the abun-
dance of the genera Streptococcus, Rothia, and Actinomyceswere higher
in cases, among whom there was also a decreased abundance of buty-
rate producing intestinal bacteria.
Microbial communities residing in other niches than the intestine
may have a signiﬁcant role in other immune-mediated diseases, such
as anelloviruses in the development of asthma [95] or skin microbiota
in themanagement of atopic dermatitis [96], but regarding the develop-
ment of islet autoimmunity, gut with its microbiota seems to be the
major early modiﬁer of the human immune system.
6. Crosstalk between microbiota and the host
Data on microbiota and its modulatory effects on the host has ex-
panded rapidly during the last ﬁve years and will be discussed else-
where. However, to summarize the big picture, current discussions
circle around three main categories: the known known, the known un-
known, and the unknownunknown. Theﬁrst category comprise data on
the crosstalk betweenmicrobiota and various organs and tissues, for ex-
ample brain [97], adipose tissue and gut [98], muscles [99], and liver
[100]. Until future studies provide further knowledge, the unknown
can only be deduced by exclusion. For example, we are still lacking
data on the importance of the unidentiﬁed reads commonly detected
in the microbiota studies; the interactions between all molecules in a
particular cell (interactomes) and in wider systems of interactingmole-
cules and cells (meta-interactomes); the crosstalk between various
kingdoms of the microbiota, and details on communication networks
between various organs and their microbiota.
7. Dysbiosis and diabetes –contemporary or causal phenomena?
Even though reports on the T1D-related changes in the gut microbi-
ota are accumulating, proving the causality has remained challenging.
Causality requires that when all possible confounders have been con-
trolled for, ceteris paribus (other things being equal), change in one var-
iable should lead to change in another variable in a repeatable and
generalizable way [101]. As long as no randomized, controlled,
placebo-controlled intervention studies showing long-term changes in
the intestinal microbial colonization and in the immunological matura-
tion that lead repeatedly to comparable changes in the T1D-associated
outcomes have been performed in man, causality between dysbiosis
and T1D remains open.
8. Hypothesis and future directions
Based on current knowledge, we hypothesize that intestinal micro-
biota may contribute to the development of T1D via a two-phased pro-
cess. The ﬁrst phase of the process starts at birth and ends with the
appearance of the ﬁrst T1D-associated autoantibodies. During that
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quired in order to establish self-tolerance and to control inﬂammatory
responses. If during that phase the gutmicrobiome tilts towards dispro-
portion between the abundance of Bacteroides, Biﬁdobacteria, and
Eschericia coli, the maturation of the immune system becomes distorted
and susceptibility to immune-mediated diseases increases. The second
phase from seroconversion to overt T1D seems to be characterized by
a reduced microbial diversity and a proinﬂammatory intestinal
dysbiosis. The mechanisms behind the spreading of the relatively local
intestinal inﬂammation towards extra-intestinal autoimmunity re-
mains to be explored in the future.
The challenge for the near future is to identify the causal relation-
ships between intestinal microbiota and T1D in man. This will require
extensive longitudinal studies with optimal methodology for collecting,
processing and storage of the stool samples. In addition, standardized
and reproduciblemethods for DNA and RNA extraction and sequencing,
for stool transcriptomics, metabolomics and metaproteomics, and for
bioinformatics are needed. We are only at the beginning of learning
about the role of the intestinal microbiome in the development of T1D
and other immune-mediated diseases. Further efforts should be di-
rected to studies on the role of the intestinal mycobiota and virome,
their interplay, and their interaction with the host and other microbes.
9. Search strategy and selection criteria
Data for this reviewwere identiﬁed through PubMed and references
from relevant articles using the search terms “microbiome”, “microbi-
ota”, “mycobiota”, “virome”,” type 1 diabetes”, and” dysbiosis”. Articles
between 2014 and 2018 were included in the initial analysis, with the
exceptions of mycobiota and other topics for which recent data were
scarcely available.
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